A prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders.

Hdl Handle:
http://hdl.handle.net/10147/132383
Title:
A prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders.
Authors:
Brown, Catherine M; Donlon, Sheila; O'Kelly, Patrick; Casey, Anne Marie; Collier, Cathal; Conlon, Peter J; Walshe, John J
Affiliation:
Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland. catherinebrownis@gmail.com
Citation:
A prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders. 2011, 33 (3):276-9 Ren Fail
Journal:
Renal failure
Issue Date:
2011
URI:
http://hdl.handle.net/10147/132383
DOI:
10.3109/0886022X.2011.559300
PubMed ID:
21401350
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21401350
Abstract:
Herein we present one of the largest single-center reports of the response of hemodialysis patients to a two-vaccine hepatitis B virus vaccination protocol in a European dialysis population. A hepatitis B recombinant DNA vaccine, HBvaxPRO, was given at a dose of 40 µg intramuscularly using a four-dose schedule at 0, 1, 2, and 12 months. Responses were (1) a titer >100 mIU/mL = patient immune, (2) a titer level 10-99 mIU/mL = give a booster dose and recheck level 2 months later, and (3) 0 ≤ 10 mIU/mL = repeat vaccination course using a different vaccine, Engerix-B. We compared responder groups in terms of titer levels for each vaccine and variables including age, gender, serum albumin, parathyroid hormone (PTH), calcium, phosphate, hemoglobin, years on dialysis, and type of dialysis access. Of the 176 patients who received the first vaccine course, 71 patients achieved immunity, that is, 40% uptake for the first vaccine. Of the 105 who failed, 72 received the second vaccine with 46 responders, that is, 64% uptake for the second vaccine. Overall, 143 of the 176 patients who entered the vaccination program completed the protocol with 117 achieving immunity, representing an 82% success rate. The only variable overall to show significance in achieving seroconversion was serum albumin (p = 0.03). Using a two-vaccine protocol, hepatitis B vaccination response was high in our population of end-stage renal disease patients.
Item Type:
Article
Language:
en
ISSN:
1525-6049

Full metadata record

DC FieldValue Language
dc.contributor.authorBrown, Catherine Men
dc.contributor.authorDonlon, Sheilaen
dc.contributor.authorO'Kelly, Patricken
dc.contributor.authorCasey, Anne Marieen
dc.contributor.authorCollier, Cathalen
dc.contributor.authorConlon, Peter Jen
dc.contributor.authorWalshe, John Jen
dc.date.accessioned2011-05-31T11:49:25Z-
dc.date.available2011-05-31T11:49:25Z-
dc.date.issued2011-
dc.identifier.citationA prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders. 2011, 33 (3):276-9 Ren Failen
dc.identifier.issn1525-6049-
dc.identifier.pmid21401350-
dc.identifier.doi10.3109/0886022X.2011.559300-
dc.identifier.urihttp://hdl.handle.net/10147/132383-
dc.description.abstractHerein we present one of the largest single-center reports of the response of hemodialysis patients to a two-vaccine hepatitis B virus vaccination protocol in a European dialysis population. A hepatitis B recombinant DNA vaccine, HBvaxPRO, was given at a dose of 40 µg intramuscularly using a four-dose schedule at 0, 1, 2, and 12 months. Responses were (1) a titer >100 mIU/mL = patient immune, (2) a titer level 10-99 mIU/mL = give a booster dose and recheck level 2 months later, and (3) 0 ≤ 10 mIU/mL = repeat vaccination course using a different vaccine, Engerix-B. We compared responder groups in terms of titer levels for each vaccine and variables including age, gender, serum albumin, parathyroid hormone (PTH), calcium, phosphate, hemoglobin, years on dialysis, and type of dialysis access. Of the 176 patients who received the first vaccine course, 71 patients achieved immunity, that is, 40% uptake for the first vaccine. Of the 105 who failed, 72 received the second vaccine with 46 responders, that is, 64% uptake for the second vaccine. Overall, 143 of the 176 patients who entered the vaccination program completed the protocol with 117 achieving immunity, representing an 82% success rate. The only variable overall to show significance in achieving seroconversion was serum albumin (p = 0.03). Using a two-vaccine protocol, hepatitis B vaccination response was high in our population of end-stage renal disease patients.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21401350en
dc.titleA prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders.en
dc.typeArticleen
dc.contributor.departmentDepartment of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland. catherinebrownis@gmail.comen
dc.identifier.journalRenal failureen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.